AP 5346

Drug Profile

AP 5346

Alternative Names: AP5346; ASK-H03; Polymer-DACH platinum conjugate - PlasmaTech Biopharmaceuticals; ProLindac

Latest Information Update: 05 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of London School of Pharmacy
  • Developer PlasmaTech Biopharmaceuticals
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 31 Dec 2011 Phase-II clinical trials in Cholangiocarcinoma in Europe (IV)
  • 01 Nov 2010 Phase-II clinical trials in Ovarian cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in France (IV) (EudraCT2010-020030-25)
  • 21 Apr 2009 Pharmacokinetics data from a Preclinical trial presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top